A new approach to prenatal treatment of extralobar pulmonary sequestration

Abstract

Fetal hydrothorax and hydrops is a frequent complication of extralobar pulmonary sequestration which is associated with a high perinatal mortality and severe respiratory insufficiency in the newborn. In a 27‐week‐old fetus with this condition, injection of 1 ml of pure alcohol and pleuro‐amniotic shunting achieved resolution of hydrops. The pregnancy progressed to term and a healthy neonate was delivered who did not require postnatal surgery. Copyright © 2000 John Wiley & Sons, Ltd.

A case report of extralobar pulmonary sequestration in a dog

“…A spiral CT with contrast angiography and magnetic resonance imaging (MRI) are the diagnostic techniques of choice [5,7,11,[19][20][21][22][23][24][25][26] . The treatment of an extralobar sequestrum is mainly by surgical excision which removes the mass completely total of the sequestrum to reduce the risk of repeated infection [2,5,7,19,20,[27][28][29] . To the best of our knowledge, this study is the first reported case of extralobar pulmonary sequestration in a mixed-breed dog that describes.…”

Percutaneous ultrasound‐guided sclerotherapy for complicated fetal intralobar bronchopulmonary sequestration

“…The prognosis is poor in cases diagnosed before 26 weeks' gestation and is associated with mediastinal shift, polyhydramnios and fetal hydrops 4,5 . Prenatal management of complicated BPS has included treatment with direct fetal furosemide and digoxin therapy 6 , thoraco-amniotic shunting 7,8 and combined absolute alcohol injection into the feeding vessel and placement of a thoraco-amniotic shunt 9 . Open fetal surgery with resection of an extralobar BPS has also been reported 8 .…”

Pathophysiological mechanisms of high-intensity focused ultrasound-mediated vascular occlusion and relevance to non-invasive fetal surgery

“…It carries additional maternal surgical risks and creates a uterine scar. Doppler ultrasound guided fetoscopic laser vessel ablation is a minimally invasive alternative, with survival rates in excess of 87.5% [101,103]; sclerosants injected into the aberrant vessel have shown high success rates, but trials have small numbers [104,105]. Complication rates are not quoted.…”